Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis

Medical Oncology

Volumn 31, Issue 1, 2014, Pages

  Yao, Zi Xiang ^a   Lu, Lin Jie ^a   Wang, Rui Jue ^a   Jin, Liang Bin ^a   Liu, Sheng Chun ^a   Li, Hong Yuan ^a   Ren, Guo Sheng ^a   Wu, Kai Nan ^a   Wang, De Lin ^a   Kong, Ling Quan ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Axillary metastases; Breast cancer; HER2; Hormone receptor; Metastatic lesions

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MESSENGER RNA; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

AXILLARY LYMPH NODE; BREAST CANCER; BREAST CARCINOMA; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; FLUORESCENCE IN SITU HYBRIDIZATION; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPH NODE METASTASIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TUMOR GROWTH; TUMOR INVASION; BREAST TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; LYMPH NODE; METABOLISM; PATHOLOGY; RECURRENT DISEASE; RISK;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECURRENCE; RISK;

MLCS; MLOWN;

EID: 84888802008     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0798-y     Document Type: Review

References (34)

1. Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14:320-68. doi: 10.1634/theoncologist.2008-0230.
2. Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26:6469-87. doi: 10.1038/sj.onc.1210477. (Pubitemid 47530601)
3. Theriault RL, Carlson RW, Allred C, et al. Breast cancer, version 3.2013. J Natl Compr Canc Netw. 2013;11:753-61.
4. Lindström LS, Karlsson E, Wilking UM, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol. 2012;30:2601-8. doi: 10.1200/JCO.2011.37.2482.
5. Dieci MV, Barbieri E, Piacentini F, et al. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis. Ann Oncol. 2013;24:101-8. doi: 10.1093/annonc/ mds248.
6. Niikura N, Liu J, Hayashi N, et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol. 2012;30:593-9. doi: 10.1200/JCO.2010.33.8889.
7. Lower EE, Glass E, Blau R, et al. HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat. 2009;113:301-6. doi: 10.1007/s10549-008-9931-6.
8. Amir E, Miller N, Geddie W, et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol. 2012;30:587-92. doi: 10.1200/JCO.2010.33.5232.
9. Thompson AM, Jordan LB, Quinlan P, et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the breast recurrence in tissues study (BRITS). Breast Cancer Res. 2010;12:R92. doi: 10.1186/bcr2771.
10. Amir E, Clemons M, Purdie CA, et al. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev. 2012;38:708-14. doi: 10.1016/j.ctrv.2011.11.006.
11. Santinelli A, Pisa E, Stramazzotti D, et al. HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int J Cancer. 2008;122:999-1004. doi: 10.1002/ijc.23051. (Pubitemid 351213996)
12. Simmons C, Miller N, Geddie W, et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol. 2009;20:1499-504. doi: 10.1093/annonc/mdp028.
13. Jensen JD, Knoop A, Ewertz M, et al. ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer. Breast Cancer Res Treat. 2012;132:511-21. doi: 10.1007/s10549-011-1610- 3.
14. Nedergaard L, Haerslev T, Jacobsen GK. Immunohistochemical study of estrogen receptors in primary breast carcinomas and their lymph node metastases including comparison of two monoclonal antibodies. APMIS. 1995;103:20-4. doi: 10.1111/j.1699-0463.1995.tb01074.x.
15. Aitken SJ, Thomas JS, Langdon SP, et al. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol. 2010;21:1254-61. doi: 10.1093/annonc/mdp427.
16. Ataseven B, Gologan D, Gunesch A, et al. HER2/neu, topoisomerase 2a, estrogen and progesterone receptors: discordance between primary breast cancer and metastatic axillary lymph node in expression and amplification characteristics. Breast Care. 2012;7:465-70. doi: 10.1159/000345467.
17. Hawkins RA, Black R, Steele RJ, et al. Oestrogen receptor concentration in primary breast cancer and axillary node metastases. Breast Cancer Res Treat. 1982;1:245-51. doi: 10.1007/s10549-011-1610-3.
18. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784-95. doi: 10.1093/annonc/mds248.
19. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-45. doi: 10.1200/JCO.2006.09.2775. (Pubitemid 350003059)
20. Wolff AC, Hammond ME, Hicks DG et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice guideline update. J Clin Oncol. http://jco.ascopubs.org/content/early/2013/10/07/JCO.2013.50.9984. Accessed 8 Oct 2013. doi: 10.1200/JCO.2013.50.9984.
21. Lower EE, Glass EL, Bradley DA, et al. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat. 2005;90:65-70. doi: 10.1007/s10549-004-2756-z. (Pubitemid 40487003)
22. Lipton A, Leitzel K, Ali SM, et al. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer. 2005;104:257-63. doi: 10.1002/cncr.21202. (Pubitemid 40993251)
23. Falck AK, Fernö M, Bendahl PO, et al. Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer? World J Surg. 2010;34:1434-41. doi: 10.1007/s00268-010- 0499-z.
24. Gong Y, Han EY, Guo M, et al. Stability of estrogen receptor status in breast carcinoma: a comparison between primary and metastatic tumors with regard to disease course and intervening systemic therapy. Cancer. 2011;117:705-13. doi: 10.1002/cncr.25506.
25. Liedtke C, Broglio K, Moulder S, et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol. 2009;20:1953-8. doi: 10.1093/annonc/mdp263.
26. Curigliano G, Bagnardi V, Viale G, et al. Should liver metastases of breast cancer be biopsied to improve treatment choice? Ann Oncol. 2011;22:2227-33. doi: 10.1093/annonc/mdq751.
27. Wang Y, Song KY, Wang JF, et al. Expression of oncogene c-erbB-2 and its relationship with clinicopathologic factors in infiltrating ductal breast cancer and metastatic axillary lymph nodes. Chin J Curr Adv Gen Surg. 2009;12:123-6. doi: 10.3969/j.issn.1009-9905.2009.02.008.
28. Jin LB, Yao ZX, Kong LQ, et al. Clinical significance of hormone receptor status detection in simultaneous axillary metastasis for hormone receptor-negative primary breast cancer patients. Chin J Clin Oncol. 2013;15:911-3. doi: 10.3969/j.issn.1000-8179.2013.15.008.
29. Tian F, Zhang JG, Zhong L, et al. Relationship of ER and HER-2 expression in primary tumor and axillary lymph node metastases of invasive ductal breast cancer. Chin J Gen Surg. 2012;21:1405-9.
30. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26:1231-8. doi: 10.1200/JCO.2007.13.5467.
31. Russell SD, Blackwell KL, Lawrence J, et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol. 2010;28:3416-21. doi: 10.1200/JCO.2009.23.6950.
32. Romond EH, Jeong JH, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30:3792-9. doi: 10.1200/JCO.2011.40.0010.
33. Bowles EJ, Wellman R, Feigelson HS, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012;104:1293-305. doi: 10.1093/jnci/djs317.
34. Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18:1133-44. doi: 10.1093/annonc/mdm271. (Pubitemid 47244357)